Tau‐related reduction of glucose metabolism in mild cognitive impairment occurs independently of <i>APOE</i> ε4 genotype and is influenced by Aβ
This study uses a data-driven singular value decomposition approach to the cross-correlation matrix between tau and fluorodeoxyglucose (FDG) images, as well as between FDG and amyloid beta (Aβ) positron emission tomography (PET) images. From a population of mild cognitive impairment subjects, we found that spatially distributed scores of tau PET are associated with an even stronger reduction of glucose metabolism, independent of the apolipoprotein E ε4 genotype and confounded by Aβ. By highlighting the more significant role of tau, rather than Aβ, on the reduction of glucose metabolism, our results provide a better understanding of their combined effects in the development of Alzheimer's disease.
Authors
- Alex Zijdenbos
- Félix Carbonell (ORCID: https://orcid.org/0000-0002-1450-0423)
- Barry J. Bedell
- Carolann McNicoll
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/alz.14625
- Citations
- 2
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Bristol-Myers Squibb
- Alzheimer's Drug Discovery Foundation
- Eli Lilly and Company
- Biogen
- AbbVie
- Meso Scale Diagnostics
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Novartis Pharmaceuticals Corporation
- Fujirebio US
- Eisai
- IXICO
- National Institutes of Health
- GE Healthcare
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering